NCT06734208View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

May 12, 2026

Study Completion Date

June 10, 2026

Conditions
Hepatic Impairment
Interventions
DRUG

Divarasib

Divarasib will be administered as a single oral dose as specified for the respective cohort.

Trial Locations (4)

32809

RECRUITING

Orlando Clinical Research Center, Orlando

33014

RECRUITING

Clinical Pharmacology of Miami, Inc., Miami

RECRUITING

Panax Clinical Research, LLC, Miami Lakes

78215

RECRUITING

American Research Corporation Inc., San Antonio

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY